Pacific Edge plans to open its first US franchise to market the company’s bladder cancer detection test, Cxbladder, to urologists in the United States by the end of the year.
The Dunedin-based firm will set up shop at the Hershey Center for Applied Research (HCAR) on America’s East Coast.
The 11,348 square-foot Pacific Edge facility will serve as an office and processing facility for the analysis of the Cxbladder test – which utilises the expression of genes in the patients’ urine to detect the presence of bladder cancer accurately and non-invasively.
Planning and construction for the new facility is currently underway and will involve about 100 new employees over the next three year.
“It’s a huge opportunity to be in the US market,” says David Darling, CEO of Pacific Edge, “It’s probably the biggest prize in the world when it comes to a responsive healthcare market that really understands what molecular diagnostics can do in a clinical setting.”
Pacific Edge has been scoping potential marketing opportunities for some time.
“As part of our business development process we met the people from HCAR in Europe at a business partnering forum, where we were looking for opportunities and various reasons in the United States to see where we should be best located strategically,” Mr Darling says.
This article is tagged with the following keywords. Find out more about MyNBR Tags
Most listened to
- Craigs' Mark Lister on Spark's results, Ebos, Port of Tauranga and Tegel
- Beertown.nz founder Martin Craig on craft beer growth
- Difficult though it is for political insiders to accept, few New Zealanders are particularly engaged in Election 2017
- Trent Fulcher on how Heartland's investment will boost Fuelled
- Nevil Gibson explains why Kraft Heinz walked away so quickly from its $US143 billion takeover bid for Unilever